PPAR-γ receptor ligands: novel therapy for pituitary adenomas
J. Clin. Invest. Anthony P. Heaney, et al. 111:1381 doi:10.1172/JCI16575 [
Go to this article.]
Figure 5Rosiglitazone inhibits somatolactotroph pituitary tumor growth in vivo. Following subcutaneous inoculation of 4-week-old female athymic nude mice with GH3 pituitary tumor cells (∼200,000 cells), animals were randomized to receive either oral rosiglitazone (150 mg/kg/d) or vehicle. Representative photograph (
a), tumor weights (
b), serum GH (
c), and PRL levels (
d) after 4 weeks of treatment with vehicle or rosiglitazone. Five animals were in each group. *
P = 0.008; **
P = 0.03.
